Targeting the Janus kinase (JAK) - signal transducer and activator of transcription (STAT) pathway through JAK inhibition has emerged as a promising therapeutic strategy for GVHD and CRS. This evidence concerns the gene SOAT1 and congenital rubella syndrome.